Larimar Therapeutics (LRMR) Cash & Equivalents (2013 - 2025)

Larimar Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $85.4 million for Q4 2025.

• Quarterly Cash & Equivalents rose 157.13% year-over-year to $85.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $85.4 million (up 157.13% YoY) and the FY2025 annual result came in at $85.4 million, up 157.13% from the prior year.
• Cash & Equivalents was $85.4 million for Q4 2025 at Larimar Therapeutics, down from $90.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $111.5 million in Q1 2023 and bottomed at $19.7 million in Q2 2022.
• A 5-year average of $58.8 million and a median of $62.4 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 377.91% — and 2025, when it sank 80.82%.
• Larimar Therapeutics' Cash & Equivalents stood at $70.1 million in 2021, then plunged by 61.73% to $26.8 million in 2022, then decreased by 0.28% to $26.7 million in 2023, then gained by 24.18% to $33.2 million in 2024, then jumped by 157.13% to $85.4 million in 2025.
• Business Quant data shows LRMR's Cash & Equivalents at $85.4 million in Q4 2025, $90.1 million in Q3 2025, and $20.6 million in Q2 2025.